Yıkıcı davranış bozuklukları olan okulöncesi çocuklarda risperidon tedavisi: Bir dosya tarama çalışması Amaç: Normal gelişim gösteren okul öncesi çocuklarda yıkıcı davranış bozukluklarının (YDB) tedavisinde risperidonun etkinliği ve güvenilirliğine dair veri toplamak. Yöntem: Bu çalışma bir üniversite hastanesi ya da özel bir çocuk psikiyatrisi kliniğine başvuran/yönlendirilen ve YDB nedeniyle risperidon tedavisi alan okul öncesi çocukla-rın tıbbi kayıt ve takiplerinin geriye dönük incelemesidir. Olguların tıbbi kayıtları psikiyatrik özellikler ve risperidon tedavisinin etkinliği ve ilişkili yan etkiler açısından incelendi. Semptom şiddeti ve iyileşme Klinik Global İzlem-Şiddet (KGİ-Ş) ve İyileşme (KGİ-İ) ölçekleri kullanılarak değerlen-dirildi. Bulgular: Olgular 21 erkek (%84) ve 4 kız çocuğun-dan (%16) oluşmaktaydı. Yaş ortalaması 45.79±11 aydı. Risperidon tedavisinin süresi 2-60 haftaydı (18.87±15.19). Risperidon doz aralığı 0.25-1 mg/gündü (0.52±0.22 mg). Başlangıç ve son-değerlendirme KGİ-Ş skorları sırasıyla 6-7 (6.56±0.5) ve 2-7 (3.96±1.3) idi. Wilcoxon t-testi başlangıç ve son-değerlendirme KGİ-Ş puanları arasında belirgin bir farklılık gösterdi (p<0.001). Olguların önemli bir kısmı (n=18; %72) hedef yıkıcı davranış semptomlarında oldukça ya da çok düzelme gösterdi. Beş olgu (%20) her hangi bir yan etki bildirmedi. En sık bildirilen yan etkiler sedasyon, iştah artışı, kilo artışı, enuresis, baş ağrısı, dermatolojik reaksiyonlar ve yorgunluk olarak saptandı. Yan etkiler genel olarak geçici ve hafif-orta şiddetliydiler. Dört olgu yan etkilerden dolayı tedaviyi bıraktı. Her hangi bir yaşam-tehdit edici yan etki bildirilmedi. Sonuç: Psikososyal girişimler YDB olan okul öncesi çocuk-larda ilk sıra tedavi olmalıdır. Ciddi derecede etkilenmiş olgularda psikofarmakolojik tedavi dikkatli bir takiple bir tedavi seçeneği olabilir. Risperidon YDB olan okul öncesi çocuklarda genel olarak güvenli ve etkili bir farmakolojik tedavi seçeneği olabilir. Bununla birlikte yüksek yan etki oranları bu konuda karar verilirken dikkatli olmayı gerektirmektedir. Bu konuda daha iyi dizayn edilmiş sistematik araştırmalara ihtiyaç vardır. Risperidone treatment in preschool children with disruptive behavior disorders: a chart review study Objective: To gather data about the efficacy and safety of risperidone in normally developing preschool children with disruptive behavior disorders (DBDs). Methods: This is a retrospective chart review study of preschool aged children who were referred to a university hospital or a private child psychiatry clinic and treated with risperidone for the presence of DBDs. Charts of the subjects were reviewed for psychiatric characteristics of the subjects as well as the efficacy and safety of risperidone. Symptom severity and improvement were assessed with Clinical Global Impression-Severity (CGI-S) and Improvement (CGI-I) scales. Results: The subjects were 21 boys (84%) and 4 girls (16%) with an age range of 26-64 months (45.79±11). The duration of risperidone treatment ranged from 2-60 weeks (18.87±15.19). Risperidone dosage ranged from 0.25-1 mg/ day (0.52±0.22 mg). Baseline and end point CGI-S scores ranged from 6-7 (6.56±0.5) and 2-7 (3.96±1.3), respectively. A nonparametric Wilcoxon t-test revealed significant differences between baseline and end point CGI-S scores (p<0.001). The majority of the subjects (n=18; 72%) showed "much" to "very much" improvement in target disruptive behavior symptoms. Overall five subjects (20%) did not report any side effects. The most frequently reported side effects were sedation, increased appetite, weight gain, enuresis, headache, dermatological reactions, and fatigue. Four subjects discontinued the medication due to side effects. Side effects were generally transient and mild to moderate in severity and no life threatening side effects were reported. Conclusions: Psychosocial interventions should be the first-line of treatment in preschool children with DBDs. Psychopharmacological treatment may be considered in severely impaired subjects with careful monitoring. Risperidone may generally be a safe and effective option in treating DBDs in preschool children; however, relatively high rates of side effects should suggest caution in the use of this drug. Further systematically designed studies are needed on this topic.
INTRODUCTION
Disruptive behavior disorders (DBDs) that include oppositional defiant disorder (ODD), conduct disorder (CD), and DBD not otherwise specified (DBD NOS) are among the most frequently diagnosed psychiatric disorders in children and adolescents. Symptoms of DBDs generally include aggression towards animate or inanimate objects, impulsivity, irritability, oppositional behavior, and low frustration tolerance (1) . Aggression is often a key target of interventions because it can lead to such negative outcomes as out-of-home placement and injury to self or others. The personal, academic, social and economic costs incurred by DBDs have made these disorders a compelling subject for research into the effectiveness of various interventions. Left untreated, severely disturbed behaviors can have a profoundly negative impact on social, family, and academic lives and have been associated with further psychopathology and criminality in later years (2) (3) (4) .
Preschool age children represent a particular subgroup of subjects with DBDs; however, data regarding characteristics and treatment of DBDs in preschool age children are limited compared to school age children and adolescents. There have been several studies regarding the characteristics and diagnosis of DBDs in preschool children (4) (5) (6) (7) (8) . Despite some level of diagnostic controversy, it has been suggested the DSM framework, with some adaptation to account for the child's developmental level, can be used effectively to identify preschool children whose disruptive behavior is impairing (5) (6) (7) (8) . Furthermore, behavior problems in preschool children have been shown to be stable over time (4, 9) . A longitudinal prospective study of a cohort of hard-tomanage 3-year-old children indicated that 48% of the children met the criteria for attention deficit-hyperactivity disorder, oppositional disorder, or conduct disorder at age 9 (9) . Preschool-age children with disruptive behavior disorders or symptoms are at significant risk for behavioral, social, familial, and academic difficulties relative to their normal counterparts (8) (9) (10) . Given that symptoms of DBDs in preschool children extend into school-age years and cause functional impairment, it is important to treat these children at an early age, as such treatment may help curtail long-term disability. The value of early intervention in DBDs has been reported previously (11, 12) .
The use of atypical antipsychotic medication for the treatment of DBD in children and adolescents is on the rise, with DBDs constituting the most frequent diagnosis among those receiving atypicals (13) . Risperidone, being the oldest atypical antipsychotic on the market, has been studied more extensively than the newer medications. There are both short-term, controlled clinical trials (14) (15) (16) , and longerterm open-label trials (17) (18) (19) (20) (21) demonstrating benefit with risperidone treatment in children with DBDs with normal or subaverage intelligence; however, data regarding the use of atypical antipsychotics in preschool children are limited in the literature. Despite there is no clear consensus on the treatment of preschool children with psychiatric disorders, including DBDs, the primary treatment modality for most very young children is generally psychotherapeutic rather than psychopharmacological (22) . In their review study, Gleason et al. (2007) further stated that psychopharmacological treatment in preschool children with psychiatric disorders could be considered if the symptoms cause significant distress or severe impairment in a child's relationships, daily routine at home, or in the child-care setting. However psychotherapeutic programs for preschool children may not be widely available or families may not access or participate in these programs. Furthermore some participating subjects may not respond to these psychotherapeutic interventions. Therefore, in daily practice, clinicians may sometimes face a need for psychopharmacological intervention in preschool children with chronic, non-remitting, and disabling behavioral/emotional problems. To date there is little literature that may help clinicians on the use of psychotropic medications in preschool children. Given the ethical and methodological difficulties of conducting prospective randomized-controlled studies in preschool children, any information on the use of psychotropic medications in preschool children might be valuable. This is a retrospective chart review study that aims to investigate the efficacy and safety of risperidone in the treatment of symptoms of DBDs in clinically referred preschool children with normal developmental history.
METHODS

Participants and Procedure
Subjects for this study were drawn from a clinical sample of preschool children who were referred to a university hospital (Istanbul University, Istanbul Medical Faculty, Child and Adolescent Psychiatry Department) and a private (PEDAM: Center for Psychiatric Research, Training, Treatment and Consultation) child psychiatry clinic in the city center of İstanbul through November 2007 to December 2009. Preschool aged children were referred to these clinics for a variety of reasons including behavioral, emotional, and developmental problems. Some of these referred preschool children with significant psychiatric problems did not respond to or have access to psychosocial interventions, and required psychopharmacological treatment including risperidone. Risperidone was started in these subjects after informed consent of the parents had been obtained. It was started at lower dosages and titrated according to the clinical response and the presence of side effects. Subjects were required to be free of known medical (such as cardiovascular disease) or neurological disorders (such as seizure disorder) that would complicate risperidone treatment. The medical records of preschool children who had been treated with risperidone were reviewed and subjects who met the following inclusion/exclusion criteria were included in the present study: a) normal developmental history b) a primary target for the treatment should be symptoms of DBDs, c) no diagnoses of autism spectrum disorders or mental retardation, and d) no use of any other psychotropic medication other than risperidone. Diagnosis of ADHD, DBDs and other comorbid disorders was made according to DSM-IV criteria. Symptom severity and improvement were assessed using the Clinical Global Impression-severity (CGI-S) and improvement (CGI-I) scales depending on the parents' and teacher's reports (if available) and clinical observation. Baseline and follow up assessments were conducted by an experienced child psychiatrist (M.C.) who has particular interest in preschool psychopathology and pediatric psychopharmacology. Subjects were followed at 2-4 week intervals and parents were allowed to contact their clinician via telephone or e-mail if they missed their appointment or if they lived in another city.
All subjects had baseline physical examination and routinely checked body weights. As a common clinical practice in young subjects on antipsychotic medications, study subjects were ordered biochemical parameters and blood counts if they had been taking risperidone for more than three months. Subjects were assessed for treatment related side effects in each visit by administering a routinely used side effect checklist. Subjects also had a physical examination for any extrapyramidal signs or symptoms during routine clinical visits. Any new onset behavioral, emotional, or somatic symptom was considered as a possible side effect even if not included in the checklist.
Medical records of the study subjects were reviewed for DSM-IV diagnoses, target symptoms of risperidone treatment, dosage and duration of risperidone treatment, improvement, and side effects related to risperidone treatment.
RESULTS
The subjects included 21 boys (84%) and 4 girls (16%) with an age range of 26-64 months (45.79±11) at the time of starting risperidone treatment. Table 1 shows the clinical characteristics of the subjects.
DSM-IV diagnoses within the sample included; ADHD (n=18; 72%), ODD (n=15; 60%), DBD NOS (n=10; 40%), OCD (n=5; 20%), motor tics (n=3; 12%), trichotillomania (n=2; 8%), speech & communication disorders (n=2; 8%) and pica (n=2; 8%). Target symptoms for risperidone treatment that are related to DBDs within the sample were; aggression towards animate or inanimate objects (n=23; 92%), irritability (n=22; 88%), oppositional/defiant behaviors (n=20; 80%), hyperactivity (n=18; 72%), anger outbursts (n=16; 64%), risky behaviors (n=12; 48%), and self harming behaviors (n=8; 32%). Other target symptoms included sleep problems (n=13; 52%), trichotillomania (n=2; 8%) and motor tics (n=2; 8%).
The duration of risperidone treatment ranged from 2-60 weeks (18.87±15.19) . Initial and maximum dosages of risperidone ranged from 0.25-0.50 mg (0.4±0.12 mg) and 0.25-1 mg (0.52±0.22 mg) respectively. Improvement in target disruptive behavior symptoms among the whole sample included; very much improvement (n=5; 20%), much improvement (n=13; 52%), mild to moderate improvement (n=4; 16%), no improvement (n=2; 8%) and minimally worsened (n=1; 4%). Baseline and end point CGI-S scores ranged from 6-7 (6.56±0.5) and 2-7 (3.96±1.3) respectively. A nonparametric Wilcoxon t-test revealed significant differences between baseline and end point CGI-S scores (Z=4.255; p<0.001). The initial dosage of risperidone was increased in 12 subjects (48%). The main reasons for dosage increases were nonresponse (n=4; 16%) or tolerance to the medication (n=8; 32%). A further improvement in disruptive behavior symptoms was observed in the majority of those subjects (n=10) after increased doses of risperidone.
Side effects fell into three groups; mild/transient (not more than five days in duration), moderate or significant, that required medication discontinuation. Overall five subjects (20%) did not report any side effects. Fifteen subjects (60%) reported mild/transient side effects that included; sedation (n=11), increased appetite (n=5), abdominal pain (n=3), flu-like symptoms (n=3), headache (n=3), dermatological reactions (n=3), nausea/vomiting (n=2), fatigue (n=2), hypersalivation/drooling (n=2), dizziness (n=1), sweating (n=1), diarrhea (n=1), encopresis (n=1), decreased appetite (n=1), and anxiety (n=1).
Nine subjects (36%) reported moderately severe side effects that included; increased appetite and weight gain (n=5; range 1.5-4.0 kg), sedation (n=4), dermatological reactions (n=2), fatigue (n=2), worsening in OCD symptoms (n=2), enuresis (n=2), headache (n=2), nausea and vomiting (n=1), encopresis (n=1), constipation (n=1), abdominal pain (n=1), flu-like symptoms (n=1) and periorbital edema (n=1).
Four subjects (16%) developed significant side effects, alongside some mild/moderate side effects, that required medication discontinuation within the first three weeks of treatment; diurnal enuresis (n=1), enuresis and encopresis (n=1), enuresis and agitation (n=1), sleep disturbance, agitation and worsening of behavioral problems (n=1). One subject did not develop diurnal enuresis after a second trial of risperidone. Medication was discontinued in two subjects (8%) due to non-response at 0.5 mg/day and the parents discontinued the medication by their own decision in another two subjects (8%).
Overall the most frequently reported side effects, regardless of severity, were sedation (n=15; 60%), increased appetite (n=10; 40%), weight gain (n=5; 20%), enuresis (n=5; 20%), headache (n=5; 20%), dermatological reactions (n=5; 20%), fatigue (n=4; 16%), flu-like symptoms (n=4; 16%), abdominal pain (n=4; 16%), nausea/vomiting (n=3; 12%), encopresis (n=3; 12%), hypersalivation/drooling (n=2; 8%) and agitation (n=2; 8%).
No subjects developed or reported any life-threatening side effects including extrapyramidal side effects (EPS). Control blood tests for liver enzymes, prolactin, lipids, and fasting blood glucose levels were conducted in 12 subjects (48%). The only significant findings in these blood tests were; mild to moderate increase in triglyceride levels in three subjects, hyperprolactinemia in three subjects, and mild elevation in liver enzymes in one subject. None of the subjects had fasting blood glucose above 126 mg/dL. None of the subjects discontinued medication due to abnormalities in blood tests.
DISCUSSION
Among preschoolers with psychiatric disorders, only a small proportion is referred for mental health treatment. A review by Gleason et al. (2007) has stated that the risks associated with untreated psychiatric disorders are not insignificant in preschool children and can be associated with child-care expulsion, inability to participate in family ADHD: Attention deficit hyperactivity disorder; CGI: Clinical Global Impression; DBD NOS: Disruptive behavior disorder not otherwise specified; OCD: Obsessive compulsive disorder; ODD: Oppositional defiant disorder * All subjects with ADHD had a comorbid diagnosis of ODD or DBD NOS ** These subjects with ADHD had a comorbid diagnosis of OCD activities, impaired peer relationships, and high-risk behaviors (22) . Despite the fact that psychosocial interventions are the mainstay of treatment in preschool children with DBDs, many subjects experience persistent behavioral problems interfering with functioning and impairing the ability to participate fully in psychosocial interventions. In line with this consideration, Gleason et al. (2007) further stated that psychopharmacological treatment in preschool children with DBDs could be considered if the symptoms cause significant distress or severe impairment in a child's relationships, daily routine at home or in the child-care setting (22) . All subjects in the present study suffered from significant disruptive behaviors, particularly aggression, irritability and out of control behaviors. They usually did not have access or respond to psychosocial interventions. Parents, particularly mothers, felt incapacitated and the majority of the parents admitted using physical punishment against their children. Half of the subjects were enrolled in nursery school or kindergarten, but they could not attend due to behavioral problems. In addition, behavioral problems of the subjects had a great impact on family life. The majority of the parents reported significant problems in their work and/or marital lives directly related to their children's disruptive behaviors. Given these characteristics, psychopharmacological treatment was deemed necessary in these subjects. There are growing numbers of studies reporting that risperidone, an atypical antipsychotic medication, has been effective in the treatment of DBDs in school aged children and adolescents with normal or subaverage intelligence (14) (15) (16) (17) (18) (19) (20) (21) . Risperidone is recommended as the first medication choice for treating children with DBD with severe aggression (1, 22) . Risperidone is also among the few medications which are approved for children less than 6 years of age (22) . A review by Pandina et al. (2006) reported that risperidone is safe and generally well tolerated in children and adolescents with DBDs (1). Side effects were generally mild to moderate in severity. Treatment related side effects were reported in up to 78 percent of the subjects and discontinuation rates due to side effects ranged between 7.8 to 13 percent (1, 20, 21) . The rates of individual side effects vary across different studies. The most frequently reported side effects in short and long term trials included somnolence/sedation, increased appetite, rhinitis, headache, weight gain, vomiting/dyspepsia, and upper respiratory tract infections (1, (14) (15) (16) (17) (18) (19) (20) (21) .
Regarding preschool aged children with behavioral / emotional disorders or problems, there are some studies reporting efficacy of risperidone in the treatment of preschool children with aggressive behaviors (23), autism and autism-related behavioral problems (24, 26) , bipolar disorder, (27) and acute stress disorder (28) . The most common side effects in these studies were sedation, increased appetite, increased prolactin levels, weight gain, headache, agitation, enuresis, and common cold symptoms. The discontinuation rate due to side effects was reported as 22.6% in one of those studies (25) . In a recent study Olfson et al. (2010) investigated the trends in antipsychotic drug use by very young children on a large population of preschool children aged between 2 and 5 years of age (29) . They found that risperidone accounted for roughly three quarters of total antipsychotic prescriptions (74%); and pervasive developmental disorder or mental retardation (28.2%), attention deficit/hyperactivity disorder (ADHD) (23.7%), and disruptive behavior disorders (12.9%) were the most common clinical diagnoses (29) . To date there is very little information on the use of risperidone among typically developing preschool children with DBDs and to our knowledge this is the first report of that kind. Risperidone was found to be effective in abating a variety of disruptive behaviors particularly aggression, irritability, and out of control behaviors in this sample. The majority of the subjects (72%) showed "much" to "very much" improvement; while two subjects showed no improvement and one subject showed mild worsening in target disruptive behavior symptoms. In previous studies on school aged children and adolescents with DBDs, risperidone treatment at doses of 0.02-0.06 mg/kg/day (with a mean maximum dosage up to 1.59 mg/day) was consistently associated with significant improvements across a range of target symptoms compared to both placebo treatment and baseline assessments (1) . Risperidone doses in our study were within this range and it was generally able to control disruptive behaviors at a mean maximum dosage of 0.52 mg /day. The findings of this study are generally consistent with data regarding the efficacy of risperidone in treating DBDs among school age children and adolescents (1, (14) (15) (16) (17) (18) (19) (20) (21) . The majority of subjects showed significant improvement in symptoms of DBDs and this improvement was acknowledged by parents', teachers' and clinicians' observations. Risperidone was also effective in the treatment of several other problems such as sleep problems, trichotillomania, and tics. Sleep problems, including difficulties initiating and maintaining sleep, have been reported in up to 50 percent of subjects with ADHD (30) . Sleep problems may have a negative impact on behavioral/ cognitive outcomes of the subjects with ADHD with or without DBDs and recent studies indicate that the majority of ADHD-related sleep difficulties may result from a combination of comorbidity (such as anxiety, depression, or disruptive behavior disorders) and medical treatment (31, 32) . More than half of the subjects (n=13; 52%) in this study reported significant sleep problems such as inability or resistance to fall in sleep, late bad time, restless sleep, frequent night awaking, or early morning awaking. Parents usually included sleep problems among primary complaints alongside with DBDs. Risperidone treatment led to "mild" to "very much" improvement in sleep problems in the majority of the subjects. Only two subjects did not report any improvement in sleep problems. Three subjects had motor tics and/or trichotillomania at the time of starting risperidone treatment. Although these did not cause significant impairment, risperidone was helpful in reducing motor tics and hair pulling in these subjects.
This study may provide data on both short and long term use of risperidone in preschool age children. The mean duration of risperidone treatment was 18.5 weeks and 9 subjects (36%) had used risperidone for more than six months at the time of assessment for the study. The great variability in the duration of treatment (2 to 60 weeks) was the result of the study design. We included subjects who discontinued medication after a few weeks or who were on the second or third week of their treatment. The majority of parents reported that risperidone was effective in controlling disruptive behaviors within the first week of treatment; however, there may be some level of tolerance to medication with long term usage. In eight subjects (32%) parents reported that the medication was no longer as effective as before. The medication was increased in these subjects after 6 to 20 weeks and all of them reported further improvement.
Regarding the safety of risperidone, the majority of subjects (80%) reported at least one side effect related to risperidone treatment. The most frequently reported side effects (≥ 20 percent) included sedation, increased appetite, weight gain, enuresis, and headache. Side effects were generally transient or mild to moderate in severity and did not require medication discontinuation. Side effects were considered as significant (requiring medication discontinuation) in four subjects (16%). The main reason(s) for medication discontinuation in these subjects were enuresis/encopresis and agitation. These side effects disappeared within two weeks of medication discontinuation without any additional interventions. We generally did not consider, and parents did not request, medication discontinuation in subjects with moderately severe side effects.
The rates and types of side effects and discontinuation rates due to side effects are generally similar to previous studies with school age children and adolescents with DBDs (1, (14) (15) (16) (17) (18) (19) (20) (21) . However there may be some developmental differences regarding the nature of the side effects such as enuresis/encopresis. In their review study on the use of risperidone in the management of DBDs in children and adolescents, Pandina et al. (2006) did not report enuresis among frequent side effects which were encountered in more than 10 percent of the subjects (1). Enuresis was reported in 20 percent of our subjects and it was the most frequent reason for medication discontinuation. Risperidone induced enuresis was previously reported in children with autism and this finding may somewhat reflect the developmental vulnerability of young children to risperidone induced enuresis (33, 34) . It may be important to note, however, that one subject who developed diurnal enuresis at the second week of the first risperidone trial, did not develop enuresis at the second trial of risperidone after one month. Another side effect of note was dermatological reactions (skin eruptions/itching) that were reported in 20 percent of the subjects. Dermatological reactions, if they occurred, appeared within the first ten days of treatment and generally disappeared within two weeks. One subject had a history of two episodes of skin eruptions possibly related to food and another subject had a history of vaccination before starting risperidone treatment. It may be important to note that dermatological reactions were not reported among frequent side effects (i.e. more than 10 percent) with risperidone treatment in children and adolescents with behavioral/emotional problems (1, 34) . It is not clear whether the relatively high rates of dermatological reactions in our study could be pertinent to young children or if this is only an incidental finding. Clinicians should directly question parents about the emergence or worsening of enuresis/encopresis and/or dermatological reactions in preschool children treated with risperidone.
None of the subjects developed any life threatening side effects including extrapyramidal side effects (EPS). Subjects were carefully examined for any physical or behavioral signs of EPS. There is a possibility that agitation and hypersalivation/drooling could be the signs of EPS, and if so, three subjects (12%) could have developed EPS and, in two of them, the medication was discontinued due to agitation. Risperidone-related hyperprolactinemia, generally without clinical signs, has been reported to occur in 10 to 76 percent of children and adolescents (1, 25, 35, 36) . In our study, twelve subjects had a laboratory work-up, and hyperprolactinemia was detected in three of them (25%) without any clinical signs.
LIMITATIONS & CONCLUSIONS
This study has several methodological limitations that should be addressed. Firstly, there are difficulties in making the diagnosis of DBDs in these very young subjects. Despite the fact that it has been suggested that diagnosis of DBDs, even diagnosis of CD, may be made using developmentally modified DSM-IV criteria in preschool children (5-8), we generally preferred a conservative approach to avoid unresolved diagnostic controversies. We made a particular diagnosis if the subject clearly met the DSM-IV criteria for ADHD or ODD. We designated subjects as DBD NOS if they had some combination of aggression, out of control behavior, oppositional behavior, irritability, and low frustration tolerance but did not meet enough criteria or were too young to enable a diagnosis of ODD or CD to be made. To date, the severity of impairment related to disruptive behaviors did not differ significantly between subjects with a diagnosis of ODD or DBD NOS. A further issue is the use of an antipsychotic medication, risperidone, in subjects with a diagnosis of ADHD. Psychostimulants are the first-line medications in the treatment of ADHD in preschool or school age children (22, 37) . The majority of the subjects in our study had a comorbid diagnosis of ADHD; however, the main problems that required psychopharmacological intervention were symptoms of DBDs, such as aggression, out of control behaviors, or oppositional behaviors, rather than hyperactivity and/or inattentiveness. In addition, more than half of the subjects had significant sleep problems that could be worsened with psychostimulant treatment. Risperidone is the first line psychopharmacological intervention in children and adolescents with DBDs (1, 22) and therefore risperidone could be preferred to treat the symptoms of DBDs and sleep problems in these subjects. The retrospective uncontrolled nature of the sample, the heterogeneity of the behavioral problems reported, the absence of a systematic structured assessment, and the relatively small sample size are other limitations that make it difficult to generalize from the findings of the study. In addition, because of the absence of validated instruments for preschool age children in our country, symptom severity and improvement was assessed using only the CGI-S and CGI-I scales. Finally, the lack of a laboratory work up for all subjects is another limitation to the interpretation of changes in biochemical parameters during risperidone treatment in very young children.
Despite the aforementioned limitations, the findings of this study may contribute to the management of preschool children with DBDs. Non-psychopharmacological interventions should be the first-line treatment in preschool children with DBDs or behavioral problems; however, in severely impaired and non-responsive cases or in the absence/ shortage of psychosocial services, psychopharmacological treatment could be an alternative. Clinicians should weigh carefully the pros and cons of psychopharmacological intervention in preschool aged children with DBDs. Given the difficulty of conducting prospective randomizedcontrolled studies in preschool children, the findings of this study may suggest that risperidone may be a safe and effective alternative in severely impaired preschool children with DBDs. Despite the frequent occurrence of side effects, no life threatening side effects were reported, side effects were generally transient and mild to moderate in severity, and side effects that led to discontinuation of the medication were reversible. Randomized controlled trials with large samples are needed to explore the efficacy and safety of the short and long term use of risperidone in preschool children with DBDs, while balancing ethical considerations and the therapeutic needs of the children.
